Tarlatamab in Small-Cell Lung Cancer after Platinum-Based …
Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung …
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Dec 11, 2024 · Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding …
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
Apr 23, 2025 · In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl …
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated ...
Apr 30, 2025 · Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter ...
Medical Management and Revascularization for Asymptomatic Carotid ...
Nov 21, 2025 · Improvements in medical therapy, carotid-artery stenting, and carotid endarterectomy call into question the preferred management of asymptomatic carotid stenosis. Whether adding …
Highly Pathogenic Avian Influenza A(H5N1) Virus Infections in Humans
Dec 31, 2024 · Highly pathogenic avian influenza A(H5N1) viruses have caused widespread infections in dairy cows and poultry in the United States, with sporadic human cases. We describe characteristics …
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal …
May 30, 2025 · Background First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated …
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
Feb 7, 2025 · Methods In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg …
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Jun 1, 2025 · Methods In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured …
Lorundrostat Efficacy and Safety in Patients with Uncontrolled ...
Apr 23, 2025 · Background Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are …